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Objective
To investigate the prevalence of physical symptoms that were
‘ever’ and ‘currently’ experienced by survivors of prostate
cancer at a population level, to assess burden and thus inform
policy to support survivors.
Patients and Methods
The study included 3 348 men surviving prostate cancer for
2–18 years after diagnosis. A cross-sectional, postal survey of
6 559 survivors diagnosed 2–18 years ago with primary,
invasive prostate cancer (ICD10-C61) identified via national,
population-based cancer registries in Northern Ireland and
Republic of Ireland. Questions included symptoms at
diagnosis, primary treatments and physical symptoms
(erectile dysfunction [ED]/urinary incontinence [UI]/bowel
problems/breast changes/loss of libido/hot flashes/fatigue)
experienced ‘ever’ and at questionnaire completion (‘current’).
Symptom proportions were weighted by age, country and
time since diagnosis. Bonferroni corrections were applied for
multiple comparisons.
Results
Adjusted response rate 54%; 75% reported at least one
‘current’ physical symptom (‘ever’ 90%), with 29% reporting
at least three. Prevalence varied by treatment. Overall, 57%
reported current ED and this was highest after radical
prostatectomy (RP, 76%) followed by external beam
radiotherapy with concurrent hormone therapy (HT, 64%).
UI (overall ‘current’ 16%) was highest after RP (‘current’
28%; ‘ever’ 70%). While 42% of brachytherapy patients
reported no ‘current’ symptoms, 43% reported ‘current’ ED
and 8% ‘current’ UI. ‘Current’ hot flashes (41%), breast
changes (18%) and fatigue (28%) were reported more often
by patients on HT.
Conclusion
Symptoms after prostate cancer treatment are common, often
multiple, persist long-term and vary by treatment method.
They represent a significant health burden. An estimated 1.6%
of men aged >45 years are survivors of prostate cancer and
currently experiencing an adverse physical symptom.
Recognition and treatment of physical symptoms should be
prioritised in patient follow-up. This information should
facilitate men and clinicians when deciding about treatment as
differences in survival between radical treatments is minimal.
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Introduction
Prostate cancer, the most common cancer in males in
developed countries, has an estimated 900 000 new cases
annually, 325 000 of which occur in Europe [1]. Driven by
ageing populations, widespread PSA testing and improved
survival, the prevalence of prostate cancer is predicted to rise
in the UK from an estimated 255 000 cases in 2010 to
831 000 cases by 2040 [2]. In Ireland, prostate cancer
currently accounts for 34% of male cancer survivors
(excluding non-melanoma skin cancers) in Northern Ireland
and 40% in the Republic of Ireland [3–4].
All prostate cancer treatments carry the potential for adverse
effects, including erectile dysfunction (ED), urinary
incontinence (UI), bowel problems, hot flashes and fatigue
[5]. As studies have not conclusively shown survival benefits
of one treatment over another for localised prostate cancer,
robust population-based estimates of prevalence and duration
of symptoms after treatment are valuable for informing
treatment decision-making [6–10].
Most studies on side effects to date are from clinical trials
that do not compare all treatment methods, exclude older
men and do not extend beyond 10 years [11–13]. The aim of
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the present study was to investigate the prevalence of physical
symptoms that were ‘ever’ experienced and are ‘currently’
experienced at a population level, assess burden and inform
policy to support medium to long-term survivors of prostate
cancer.
Patients and Methods
The study took place in Ireland. Northern Ireland has a
predominantly publically funded healthcare system, whereas
the Republic of Ireland has a mixture of public and private
healthcare. The same approach was used in both settings to
identify and recruit participants. All men diagnosed with
invasive prostate cancer (ICD10 C61) between 1 January 1995
and 31 March 2010 and alive at 31 March 2011 were
identified through population-based cancer registries
(Northern Ireland 5 519 men; Republic of Ireland 17 304
men). A random sample of survivors was screened for
eligibility by healthcare providers (n = 12 322, 52% of total
sampling frame). Eligible survivors were: aware of their
diagnosis, English speaking-resident in either Northern
Ireland or the Republic of Ireland, and well enough to
complete a questionnaire (in particular had no cognitive
impairment).
In Northern Ireland, eligibility was checked by research
nurses, or the patient’s GP. In the Republic of Ireland, the
patient’s GP confirmed eligibility. In both areas, survivors
whose eligibility was not confirmed (e.g. non-response of GP
were excluded). After this process, 6 559 (53% of the random
sample) were deemed eligible for invitation to complete a
postal questionnaire (Fig. 1).
A questionnaire including the European Organisation for the
Research and Treatment of Cancer (EORTC) QLQ C30, PR25,
EQ5D-5L, DASS 21 and Decisional Regret Scale was developed
following literature review with clinician and patient input
[14–18]. Questions included sociodemographic characteristics
and pre-diagnosis symptoms (urinary problems: increased
After randomisation 12 322 prostate cancer survivors were screened for eligibility to participate  
6 559 (53.2%) survivors eligible to be sent questionnaire 
297 (4.5%) Ineligible after questionnaire  
despatch and removed from denominator
92 (1·4%) cognition/ other health problems
67 (1·0%)Patient deceased
44 (0·7%)Patient unaware of diagnosis
94 (1·4%) Incorrect address/gone away
Overall adjusted response
Total Sampling Frame
Prostate cancer survivors in RoI and NI1/1/1995 to 31/3/2010 
(RoI N = 17 304; NI N = 5 519)
5 763 (46.8%) excluded following eligibility screening 
1 724 (14·0%) Clinical non-response/clinical refusal/i nactive GP/ Patient changed 
GP
594 (4·8%) Cognition/other health problems
503 (4·1%) Patient deceased
362 (2·8%) Patient unaware of diagnosis
127 (1·0%) GP unaware of diagnosis/unconfirmed diagnosis
286 (2·3%) Other health problems reported by GP(NI only)
2 167 (17·6%) Other
rate = 54%          (3 348/6 262)
Fig. 1 Recruitment of prostate cancer survivors.
RoI, Republic of Irleand; NI, Northern Ireland.
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frequency, pain urinating, blood in urine), bowel problems
(diarrhoea, constipation), and/or sexual dysfunction (ED and
loss of libido). Information on the last two were requested ‘ever’
after treatment, ‘currently’ at questionnaire completion and
pre-diagnosis. A list of prostate cancer treatment methods was
included and survivors were asked to indicate all treatments
received, with dates. Specific questions were asked about seven
potential disease- or treatment-related symptoms at two time-
points; ‘ever’ (i.e. anytime since treatment) and ‘current’ (i.e. at
time of questionnaire completion). The symptoms considered
were UI, ED, loss of libido, bowel problems, breast changes, hot
flashes and fatigue.
The draft questionnaire was pre-tested among 32 survivors of
prostate cancer for acceptability, ease of understanding and
face validity, and modified accordingly. Questionnaires were
dispatched between April and September 2012. Each man
received a cover letter, information sheet, consent form and
freepost return envelope with their questionnaire. Non-
responders received up to two written reminders. Date of
diagnosis, clinical stage, and Gleason grade at diagnosis were
extracted from cancer registry databases. The Gleason grade
is collected and categorised as low (<5), medium (6–7) and
high (>8) and not as raw data by the registry. Additional
information was sourced for staging/Gleason grade for
responders from Northern Ireland, as these data were
incomplete in routine data for earlier years.
For survivors who answered some treatment or physical
symptom questions, but omitted others from that section, a ‘no’
response was assumed. Non-response to all of five treatment
questions (3%, n = 93), or all 14 symptom questions (3%, n =
102), were coded as ‘missing’ but retained in analyses.
To investigate whether symptoms varied by time since
diagnosis, respondents were categorised into three groups:
2–4.9 years, 5–9.9 years and ≥10 years after diagnosis. To
study symptoms by treatment, a variable was created based
on a mutually exclusive hierarchy of treatments: each man
was categorised once based on primary treatment(s)
received: radical prostatectomy (RP) at any time following
diagnosis (with or without other treatments); external
beam radiotherapy (EBRT) with concurrent hormone
therapy (HT) within 6 months; EBRT without HT;
brachytherapy (BT), excluding survivors with previous
EBRT or RP; HT alone without RP, EBRT or BT;
chemotherapy alone; monitoring including active
surveillance or watchful waiting.
Survivors were also categorised as: (i) currently on HT, (ii)
previously received HT and (iii) never had HT. Pretreatment
and post-treatment experience was compared for loss of
libido and ED.
Comparisons of symptom proportions across treatment groups
were tested for significance at the 5% level using two-sided
z-tests based upon weighted counts rounded to the nearest
whole number, with differences in overall distributions tested
using chi-square tests. Bonferroni corrections were applied to
account for multiple comparisons. The Clopper–Pearson
interval method was used to generate exact 95% binomial CIs
for weighted proportion estimates [19].
To extrapolate results to the entire prostate cancer survivor
population, weighted proportions of symptoms were
computed. Respondents’ characteristics were compared with
those of all prostate cancer survivors in Ireland (i.e. the total
sampling frame) and the proportions with each symptom was
adjusted with weights based on country, age at diagnosis and
time since diagnosis.
Results
In all, 3 348 men responded, representing a 54% response
rate after adjusting for eligibility following questionnaire
dispatch. Respondents’ mean (SD) age was 64.9 (7.6) years.
Compared with all prostate cancer survivors, respondents
were younger at diagnosis (chi-square 49.6; P < 0.001),
diagnosed more recently (chi-square 164.8; P < 0.001), had
their cancer staged (chi-square 673.0; P < 0.001) and graded
(chi-square 653.1; P < 0.001) (Table 1). Two-thirds of
respondents (64%) had presented with early disease (stage I/
II), while 65% had an intermediate Gleason grade (5–7) at
diagnosis. Almost half (48%) were surveyed 2–4.9 years after
diagnosis, 32% at 5–9.9 years and 20% at ≥10 years. Those in
the ≥10-year group were younger at diagnosis, less often had
stage I/II disease and more often had low-grade disease
compared with those diagnosed more recently (all
comparisons P < 0.001). They also more often reported RP
treatment and less often BT or EBRT with HT (all
comparisons P < 0.001). At diagnosis over half (51.2%) of
men reported urinary frequency, 18.8% ED and 14.7% loss of
libido. There were no significant variations in pretreatment
symptoms reported between groups diagnosed at different
time-periods (Table 2). The responder’s treatment categories
were compared with data from both cancer registries taken in
2001. The levels of chemotherapy (2% responders, 1.4%
registry; P = 0.11), HT (45% responders, 44% registry; P =
0.46) and RP (27% responders, 38% registry; P < 0.01) were
within the range of the overall prostate cancer population.
The levels of radiotherapy were higher among responders at
58%, 24% registry (P < 0.01), in keeping with, but not
completely explained by increased use over time (Republic of
Ireland average 41% for 2007–2011).
‘Ever had’ Physical Symptoms (Weighted
Proportions)
Overall, 90% of respondents, reported ‘ever’ experiencing at
least one of the seven possible physical symptoms investigated
after treatment: 61% reported at least three, 20% reported
© 2015 The Authors
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Table 1 Characteristics of prostate cancer populations.
All survivors
(N = 22 823)
Random sample
(n = 12 322)
Eligible for study
(n = 6 559)
Responders
(n = 3 348)
Non-responders
(n = 3 211)
N (%)
Age at diagnosis, years
0–59 5 046 (22.1) 2 039 (16.5) 1 329 (20.3) 799 (23.9) 530 (16.5)
60–69 10 212 (44.7) 4 891 (39.7) 2 939 (44.8) 1 631 (48.7) 1 308 (40.7)
≥70 7 565 (33.1) 5 392 (43.8) 2 291 (34.9) 918 (27.4) 1 373 (42.8)
Time since diagnosis, years
2–5 9 569 (41.9) 5 340 (43.3) 3 101 (47.3) 1 614 (48.2) 1 487 (46.3)
5–9.9 9 776 (42.8) 4 324 (35.1) 2 114 (32.2) 1 075 (32.1) 1 039 (32.4)
≥10 3 478 (15.2) 2 658 (21.6) 1 344 (20.5) 659 (19.7) 685 (21.3)
TNM stage*
I/II 12 761 (55.9) 5 792 (47.0) 3 817 (58.2) 2 126 (63.5) 1 691 (52.7)
III 2 122 (9.3) 1 130 (9.2) 947 (14.4) 612 (18.3) 335 (10.4)
IV 690 (3.0) 445 (3.6) 267 (4.1) 141 (4.2) 126 (3.9)
Unknown 7 250 (31.8) 4 955 (40.2) 1 528 (23.3) 469 (14.0) 1 059 (33.0)
Gleason grade*
2–4 1 578 (6.9) 923 (7.5) 472 (7.2) 212 (6.3) 260 (8.1)
5–7 11 766 (51.6) 4 996 (40.5) 3 609 (55.0) 2 186 (65.3) 1 423 (44.3)
8–10 2 865 (12.6) 1 594 (12.9) 1 060 (16.2) 625 (18.7) 435 (13.5)
Unknown 6 614 (29.0) 4 809 (39.0) 1 418 (21.6) 325 (9.7) 1 093 (34.0)
*Further information was sourced for TNM stage and Gleason grade for Northern Ireland responders only. This is reflected in the lower percentage with stage unknown among
responders compared with the other columns.
Table 2 Characteristics of responders by time since diagnosis.
2–4.9 years after
diagnosis (n = 1 614)
5–9.9 years after
diagnosis (n = 1 075)
≥10 years after
diagnosis (n = 659)
All respondents
(n = 3 348)
N (%)
Age at diagnosis, years
0–59 340 (21.1) 255 (23.7) 204 (31.0) 799 (23.9)
60–69 750 (46.5) 534 (49.7) 347 (52.7) 1 631 (48.7)
≥70 524 (32.5) 286 (26.6) 108 (16.4) 918 (27.4)
Age at questionnaire completion, years
0–59 186 (11.5) 45 (4.2) 12 (1.8) 243 (7.3)
60–69 637 (39.5) 346 (32.2) 102 (15.5) 1 085 (32.4)
≥70 791 (49.0) 684 (63.6) 545 (82.7) 2 020 (60.3)
Stage
Stage I/II 1 120 (69.4) 670 (62.3) 336 (51.0) 2 126 (63.5)
Stage III 323 (20.0) 183 (17.0) 106 (16.1) 612 (18.3)
Stage IV 81 (5.0) 36 (3.3) 24 (3.6) 141 (4.2)
Unknown 90 (5.6) 186 (17.3) 193 (29.3) 469 (14.0)
Gleason grade
Low (2–4) 66 (4.1) 51 (4.7) 95 (14.4) 212 (6.3)
Intermediate (5–7) 1 035 (64.1) 769 (71.5) 382 (58.0) 2 186 (65.3)
High (8–10) 356 (22.1) 170 (15.8) 99 (15.0) 625 (18.7)
Unknown 157 (9.7) 85 (7.9) 83 (12.6) 325 (9.7)
Symptom at diagnosis
Frequency of urine 821 (50.9) 547 (50.9) 346 (52.5) 1 714 (51.2)
Pain while urinating 103 (6.4) 88 (8.2) 65 (9.9) 256 (7.6)
Blood in urine 94 (5.8) 72 (6.7) 53 (8.0) 219 (6.5)
ED 356 (22.1) 184 (17.1) 91 (13.8) 631 (18.8)
Loss of libido 247 (15.3) 163 (15.2) 83 (12.6) 493 (14.7)
Back pain 261 (16.2) 161 (15.0) 84 (12.7) 506 (15.1)
Primary treatment
RP 374 (23.2) 305 (28.4) 255 (38.7) 934 (27.9)
EBRT with concurrent HT 383 (23.7) 179 (16.7) 68 (10.3) 630 (18.8)
EBRT without concurrent HT 484 (30.0) 391 (36.4) 213 (32.3) 1 088 (32.5)
BT 87 (5.4) 33 (3.1) 4 (0.6) 124 (3.7)
HT 147 (9.1) 91 (8.5) 72 (10.9) 310 (9.3)
Monitoring 102 (6.3) 44 (4.1) 18 (2.7) 164 (4.9)
Missing 34 (2.1) 31 (2.9) 28 (4.2) 93 (2.8)
Results are not weighted for survey non-response bias. Chemotherapy was omitted because there were <5 respondents. Respondents may have more than one symptom.
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four, one in eight (12.5%) reported five, 6% reported six and
2% reported all seven. The most common were ED (68%),
loss of libido (58%) and fatigue (55%). There was significant
variation in ‘ever’ had symptoms by time since diagnosis.
Loss of libido was more common in men 2–4.9 years since
diagnosis compared with those ≥10 years after diagnosis (60%
vs 54%, respectively; P = 0.010). Bowel problems (26% of all
respondents) and fatigue (55% of all respondents) were less
common among those ≥10 years after diagnosis compared
with other diagnosis periods, bowel (2–4.9 years, P < 0.001;
5–9.9 years, P = 0.004), fatigue (2–4.9 years, P < 0.001; 5–
9.9 years, P = 0.007) (Table 3).
‘Current’ Physical Symptoms (Weighted Proportions)
Three-quarters of respondents reported at least one ‘current’
symptom with 29% reporting three or more symptoms and
4% at least five symptoms. About 65% reported currently
having ED, UI and/or bowel problems, and 57% reported at
least one of the following; loss of libido, breast changes,
fatigue or hot flushes (Fig. 2). There was no significant
difference in proportions of ‘current’ symptoms between
groups diagnosed during different periods. For each
symptom, ‘current’ proportions were lower than ‘ever’. The
biggest differences were for fatigue (ever, 55%; current, 22%),
hot flushes (ever, 39%; current, 6%) and UI (ever, 37%;
current, 16%), and the smallest for ED (68% vs 57%). One-
quarter of survivors (25%) reported no ‘current’ physical
symptoms (Table 3).
Pretreatment and Post-Treatment Comparisons
Pretreatment and post-treatment comparisons were possible
for ED and loss of libido. Before diagnosis, 19% reported ED,
increasing with age at diagnosis from 16% of those aged
<60 years to 21% of men aged >70 years. ED as a new
current symptom after treatment was reported by 43%, while
5% reported ED pretreatment, but not currently. This varied
by primary treatment being highest after RP. Loss of libido
was reported before diagnosis by 15% of survivors; 5%
reported this pretreatment but not currently; and 46% report
‘current’ loss of libido but not pretreatment (Fig. 3).
Table 3 Symptoms (‘current’ and ‘ever’) reported by prostate cancer survivors, by primary treatment method (weighted for country, age at diagnosis
and time since diagnosis).
RP EBRT with
concurrent
HT
EBRT without
concurrent
HT
BT HT Monitoring Missing All
respondents
Percentage of men reporting symptom, (95% CI)
Average
age at
diagnosis,
years
60.5 66.4 67.1 61.7 73.5 67.9 69.0 64.9
UI
Ever had 70.3 (67.2–73.3) 24.3 (20.8–28.0) 27.3 (24.7–3.0) 28.5 (20.7–37.3) 21.3 (17.1–26.1) 12.1 (7.6–18.1) 23.5 (15.7–33.0) 37 (35.4–38.7)
Current 27.8 (24.9–30.8) 10.7 (8.3–13.5) 11.8 (10.0–13.9) 8.1 (4.0–14.4) 14.5 (10.9–18.7) 6.7 (3.4–11.6) 12.7 (7.0–20.8) 15.8 (14.6–17.1)
Loss of libido
Ever had 59.5 (56.2–62.7) 74.4 (70.6–77.9) 55.7 (52.8–58.7) 41.5 (32.7–50.7) 58.6 (53.1–63.9) 26.1 (19.5–33.5) 37.3 (27.9–47.4) 57.8 (56.1–59.5)
Current 47.0 (43.7–50.3) 58.0 (53.9–62.1) 43.1 (40.2–46.1) 26.0 (18.5–34.7) 51.5 (46.0–56.9) 21.8 (15.8–28.9) 29.4 (20.8–39.3) 45.5 (43.8–47.2)
ED
Ever had 87.6 (85.3–89.7) 78.7 (75.1–81.9) 59.6 (56.7–62.5) 58.5 (49.3–67.3) 59.2 (53.7–64.5) 26.1 (19.5–33.5) 42.2 (32.4–52.3) 68.2 (66.6–69.8)
Current 75.5 (72.6–78.3) 64.2 (60.2–68.1) 50.2 (47.2–53.1) 43.1 (34.2–52.3) 50.9 (45.4–56.3) 20.6 (14.7–27.6) 29.4 (20.8–39.3) 57.2 (55.5–58.9)
Bowel
problems
Ever had 16.6 (14.2–19.2) 41.0 (36.9–45.1) 33.1 (30.4–36.0) 21.1 (14.3–29.4) 14.2 (10.7–18.4) 3.6 (1.3–7.7) 9.8 (4.8–17.3) 25.5 (24.1–27.1)
Current 9.2 (7.4–11.3) 22.0 (18.7–25.6) 19.2 (16.9–21.6) 7.3 (3.4–13.4) 9.2 (6.3–12.8) 2.4 (0.7–6.1) 4.9 (1.6–11.1) 14.2 (13.1–15.5)
Breast changes
Ever had 6.2 (4.7–8.0) 39.6 (35.6–43.7) 17.7 (15.5–20.0) 1.6 (0.2–5.8) 22.8 (18.4–27.6) 2.4 (0.7–6.1) 4.9 (1.6–11.1) 17.2 (16.0–18.6)
Current 3.1 (2.1–4.5) 20.0 (16.8–23.5) 8.7 (7.1–10.4) 1.6 (0.2–5.8) 17.8 (13.8–22.3) 1.8 (0.4–5.2) 1.0 (0.0–5.3) 9.3 (8.3–10.3)
Hot flushes
Ever had 15.7 (13.4–18.3) 79.9 (76.4–83.1) 40.4 (37.5–43.3) 11.4 (6.4–18.4) 60.1 (54.6–65.3) 6.1 (2.9–10.9) 5.9 (2.2–12.4) 38.7 (37.1–40.4)
Current 7.0 (5.4–8.8) 27.7 (24.1–31.5) 14.5 (12.5–16.7) 2.4 (0.5–7.0) 40.5 (35.3–46.0) 3.6 (1.3–7.7) 2.0 (0.2–6.9) 16.0 (14.8–17.3)
Fatigue
Ever had 50.4 (47.1–53.7) 74.0 (70.2–77.5) 63.4 (60.5–66.2) 44.7 (35.7–53.9) 42.0 (36.7–47.5) 8.5 (4.7–13.8) 18.6 (11.6–27.6) 54.9 (53.2–56.6)
Current 18.1 (15.6–20.7) 31.5 (27.7–35.4) 22.8 (20.4–25.3) 13.0 (7.6–20.3) 28.4 (23.7–33.5) 4.2 (1.7–8.5) 4.9 (1.6–11.1) 21.7 (20.3–23.2)
No symptom
Ever had 4.3 (3.1–5.9) 1.2 (0.5–2.5) 9.6 (8.0–11.5) 17.1 (10.9–24.9) 10.9 (7.8–14.8) 58.2 (50.3–65.8) 37.3 (27.9–47.4) 10.4 (9.4–11.4)
Current 15.5 (13.2–18.0) 16.5 (13.6–19.8) 29.4 (26.8–32.2) 41.5 (32.7–50.7) 19.5 (15.4–24.2) 63.6 (55.8–71.0) 49.0 (39.0–59.1) 25.2 (23.7–26.7)
Any symptom
Ever had 95.7 (94.1–96.9) 98.8 (97.5–99.5) 90.4 (88.5–92.0) 82.9 (75.1–89.1) 89.1 (85.2–92.2) 41.8 (34.2–49.7) 62.7 (52.6–72.1) 89.6 (88.6–90.6)
Current 84.5 (82.0–86.8) 83.5 (80.2–86.4) 70.6 (67.8–73.2) 58.5 (49.3–67.3) 80.5 (75.8–84.6) 36.4 (29.0–44.2) 51.0 (40.9–61.0) 74.8 (73.3–76.3)
Results were weighted for survey non-response bias. Chemotherapy was omitted because there were <5 respondents. Respondents may have more than one symptom.
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Variations in ‘current’ Physical Symptoms by Primary
Treatment
Among men treated with RP proportions of ‘current’ ED
(76%) and UI (28%) were higher than the average for all
respondents (weighted proportions; P < 0.001) while bowel
problems (9%), hot flushes (7%) and breast changes (3%)
after RP were lower than average (P < 0.001 for all three
comparisons).
Men treated with EBRT with concurrent HT reported the
highest proportions of current bowel problems (20%)
compared with HT (9%), RP (9%), BT (7%) or monitoring
(2%). Survivors treated by EBRT with concurrent HT,
compared with those who had EBRT without concurrent HT,
reported more ‘current’ loss of libido (58% vs 43%, P <
0.001), ED (64% vs 50%, P < 0.001), breast changes (20% vs
9%, P < 0.001), hot flushes (28% vs 15%, P < 0.001) and
fatigue (32% vs 23%, P < 0.001).
Those treated with BT reported lower than average
proportions of ‘current’ ED (43%), loss of libido (26%), hot
flushes (2%), and breast changes (2%); 42% of this group
reported no ‘current’ problems.
Men treated with HT alone reported high proportions of
‘current’ loss of libido (52%), ED (51%), hot flushes (41%)
and fatigue (28%), while 20% reported no ‘current’ physical
symptoms.
Of the men on monitoring, 64% reported no ‘current’
physical symptoms, higher than other groups (P < 0.001).
One in five men on monitoring reported loss of libido or ED
(21%, only slightly higher than pretreatment average level of
19%) or loss of libido (22%). Other symptoms were less
common in the monitoring group [UI (7%), hot flushes (4%),
fatigue (4%), bowel problems (2%) and breast changes (2%)]
(Table 3).
Variation in ‘current’ Symptoms by HT
Overall, 45% reported receiving HT at some point after
diagnosis. Current use of HT (19%) compared with past use
(26%), and never used (55%) was associated with more hot
flushes, (54% current vs 15% past vs 4% never), loss of libido
(62% current vs 50% past vs 38% never), breast changes (23%
current vs 14% past vs 2% never) and fatigue (38% current vs
23% past vs 16% never) (all comparisons P < 0.001) (Fig. 4).
Discussion
This large population-based study adds to the literature in
this area by examining seven disease-specific physical
symptoms of men of all ages with prostate cancer up to
18 years after diagnosis. All treatment methods were included
in two countries with high standards of services and patient
care. This has allowed us to estimate the population burden
of physical symptoms as reported by men, their patterns
following different treatments and their ‘persistence’.
Considering the uncertainties about optimal treatment from a
clinical outcome perspective, this type of information on
patients-reported outcomes is potentially extremely valuable
for informing treatment decision-making.
All respondents n=3,348
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Breast 
changes
Hot 
flashes
None of these
43%
Fatigue
5%
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35%
All respondents n = 3, 348
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Fig. 2 (a) ‘Current’ ED, UI and bowel problems. (b) ‘Current’ loss of libido,
breast changes, fatigue and hot flushes.
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The burden of symptoms is high, with many survivors
reporting multiple symptoms. Nine out of 10 men reported at
least one of the seven possible symptoms at some point after
diagnosis and three-quarters reported at least one as ‘current’.
However, about one in 10 survivors reported no symptoms at
any time and 25% were currently symptom free.
Over half (57%) reported ‘current’ ED, almost half (46%)
reported loss of libido and one in six reported ‘current’ UI,
with fatigue a common complaint. UI and ED were more
common after RP compared with other treatments, and bowel
problems were most common after EBRT. The pattern of
these symptoms was as documented in smaller studies
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reporting on specific treatments [7,10,20–21]. However, the
present study, which looks at survivors at population level ,
allows an estimate of total burden.
For ED, ‘current’ levels of 57% and ‘ever’ levels of 68% were
reported. This work extends that of Korfage et al. [22], who
found that at 52 months after treatment, 88% of men treated
with RP and 64% of those who had EBRT with concurrent
HT reported ED. We found similar high levels by examining
men up to 15 years after diagnosis supporting the Korfage
et al. assertions that ED is likely to be permanent if present
12 months or more after treatment.
The effect of HT in improving survival has been documented,
but at a cost of symptoms such as loss of libido, fatigue, hot
flushes and breast changes [10,23]. Consistent with this, and
reported for a large cohort, those currently on HT were 10-
times more likely to report breast changes and hot flushes
than those who never had HT. High levels of fatigue for
those on HT is similar to clinical studies [24].
An important part of our present analysis related to the
prevalence of symptoms at different times since diagnosis.
The lower proportion of bowel problems reported by
survivors diagnosed ≥10 years ago probably reflects lower
rates of EBRT in that cohort (confirmed by cancer registry
data), as well as improvements in technologies. The fact
that the proportions who reported ‘ever’ and ‘current’
symptoms were similar in each survival period indicates a
need for ongoing support after treatment for prostate
cancer.
Implications
Current UK guidelines recommend that survivors and their
partners are given opportunities to discuss psychosexual
problems and that counselling on sexual problems and UI is
available as long as needed [6]. Our present results suggest
there is likely to be a large need, with three-quarters of men
reporting at least one physical symptom, almost 60% ‘current’
ED and one in six reporting ‘current’ UI.
Based on the present work, of the 22 823 prostate cancer
survivors resident in Ireland at the time of the study, we
estimate that 17 100  300 had at least one ‘current’ physical
symptom, including ED (13 100  400) loss of libido (10 400
 400), fatigue (5 000  300) and UI (3 600  300). Based
upon the 2011 Censuses in both countries, we estimate that
1.6% of the male population aged ≥45 years is a prostate
cancer survivor with a ‘current’ physical symptom: 1.2% with
ED and 1% with loss of libido. This represents a significant
number of men who require ongoing care. The information
in the present study could also be used to help inform
decisions about investigation and treatment of prostate cancer
and survivors’ expectation of symptoms [6]. Recognition and
treatment of physical symptoms should be prioritised in
patient follow-up.
Strengths
Unlike other similar patient-reported outcome studies in
prostate cancer, the present study included men of all ages,
treated with all available methods [25–26]. It also covered a
longer period since diagnosis [7,20]. High-quality cancer
registries provided the basis for sampling and this allowed
population representativeness to be assessed and proportions
to be weighted, so that estimates are of the symptom burden
in the entire survivor population. Self-reported treatment was
compared with treatment information from each registry;
congruence for RP was 86% in Northern Ireland and 70% in
the Republic of Ireland, and for EBRT was 96% in Northern
Ireland and 75% in the Republic of Ireland. Weighting
allowed us to address some demographic aspects of non-
response.
Limitations
As with many questionnaire studies, older persons were less
likely to respond but weighted proportions allowed adjustment
for this [5]. In addition, as a cross-sectional study, comparisons
between groups diagnosed at different time-periods have
limitations owing to changing treatment, investigation patterns
and different patient profiles. We recognise that accuracy of
recall as a potential limitation, for example, the 4% of survivors
in the monitoring group reporting ‘current’ hot flushes may
represent contamination of treatment recall with survivors not
recognising that they are having HT.
While we have documented symptoms reported by survivors
of prostate cancer, we recognise that not all can be attributed
to prostate cancer treatments, e.g. ED increases with age
[27,28]. We have reported pretreatment and post-treatment
levels of ED and these increased with age from 16% in men
aged <60 years, to 18.7% in men aged 60–69 years and 20.4%
in men aged ≥70 years. The same men responded with to
post-treatment levels of ED of 66.4% aged <60 years, 61.5%
aged 60–69 years and 45.9% aged ≥70 years. These figures
reflect the higher rates of RP in younger men and monitoring
in older men. UI in general male populations, without
prostate cancer, has been estimated to be between 3% and
11% [29]. UI among the Irish population has been reported
at 4.5% for men aged >50 years, ranging from 2 to 4% for
men aged 50–64 years to 4–7% for men aged 65–74 years
and 6–11% for those aged >75 years [30], which is lower
than the 16% ongoing UI reported after treatment. Some of
the reported physical symptoms may, however, be caused by
co-morbidities, or other treatments such as breast changes
caused by commonly used medications [29]. Future studies
should collect normative data for the male population to
better determine treatment effects.
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In conclusion, physical symptoms after prostate cancer
treatment are common, often multiple and persist years after
diagnosis, representing a large health burden.
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